Web Exclusive: What Is a "Good Death?"
April 01, 2009 – Kathy LaTour
Web Exclusive: Resolving Your Own Death
March 25, 2009 – Kathy LaTour
Web Exclusive: Understanding Hospice
March 20, 2009 – The American Hospice Foundation
Web Exclusive: Find a Clinical Trial That's Right for You
March 18, 2009
Web Exclusive: Find a Clinical Trial That's Right for You
March 18, 2009
Web Exclusive: Eulogy for Dr. Phillip Berman
March 18, 2009
Web Exclusive: A Granddaughter's Eulogy
March 17, 2009 – Heather Venrick
Calming Cancer Pain
March 17, 2009 – Kathy LaTour
Excerpt: When Hormone Therapy Can Stress You Out
March 17, 2009 – Ed Weinsberg
Treatment Snapshot
March 17, 2009
Choosing the Right Plan
March 13, 2009 – Christy Schmidt
Lymphoma, Myeloma & Prostate Cancer
March 13, 2009 – Elizabeth Whittington
When Do I Tell Her?
March 13, 2009 – Jasan Zimmerman
Web Exclusive: Caregiving Resources
March 13, 2009
What Can Patients Do to Reduce a Spouse's Stress?
March 13, 2009 – Lacey Meyer
Web Exclusive: Childhood Survivors Face Increased Risks
March 13, 2009 – Teresa McUsic
Soy Story
March 13, 2009 – Lena Huang
Web Exclusive: An Amazing Journey with Remarkable Women
March 13, 2009 – Kathy LaTour
An Incredible Journey
March 13, 2009 – Kathy LaTour
Web Exclusive: Identifying Insurance Challenges (and Solutions)
March 13, 2009 – Elizabeth Whittington
Medicare Resources
March 13, 2009
New Legislation Focuses on Helping Patients
March 13, 2009 – Teresa McUsic
The Four Parts of Medicare
March 13, 2009
Should Breast Cancer Patients Make the Switch?
March 13, 2009 – Beverly A. Caley
Web Exclusive: Types of Non-Hodgkin Lymphoma
March 13, 2009 – The American Cancer Society
Web Exclusive: Cognitive Changes
March 13, 2009
Web Exclusive: Types of Thyroid Cancer
March 13, 2009 – The National Cancer Institute
My Extended Vacation
March 13, 2009 – Gary Grieger
Does Treatment Differ for Older Patients?
March 13, 2009 – Heather L. Van Epps, PhD
New Blood
March 13, 2009 – Susan Kreimer
For the Caregiver: Brain Nourishment
March 13, 2009 – Laura Beil
The Low-Iodine Diet
March 13, 2009 – Charlotte Huff
Conquer Prostate Cancer: How Medicine, Faith, Love and Sex Can Renew Your Life
March 13, 2009 – Kathy LaTour
Childhood Cancer Survivors Skip Needed Mammograms
March 13, 2009 – Elizabeth Whittington
Young Patients Make Their Mark in Art Exhibit
March 13, 2009 – Lacey Meyer
U.S. Surgeon General's Office Releases Updated Family Health History Program
March 13, 2009 – Lacey Meyer
Kathy Bates Reveals Her Survivorship Status
March 13, 2009 – Lacey Meyer
Q&A: KRAS Testing
March 13, 2009 – Len Lichtenfeld, MD
Supplements Offer No Prostate Cancer Protection
March 13, 2009 – Lena Huang
Crossing Gender Lines
March 13, 2009 – Kathy LaTour
CancerCare Telephone Education Workshop: Seventh Annual Cancer Survivorship Series
March 13, 2009 – Elizabeth Whittington
Ad Campaign Targets Health Care Reform
March 13, 2009 – Elizabeth Whittington
Message From the Editor
March 13, 2009 – Debu Tripathy, MD
Treatment Updates
February 18, 2009 – Susan R. Peck, PhD
The Ins and Outs of Ports
February 18, 2009 – Curtis Pesmen
Stressed Out
February 18, 2009 – Lacey Meyer
Battling Cancer Again
February 18, 2009 – Teresa McUsic
Warrior Survivors
February 18, 2009 – Kathy LaTour
Mind Games
February 18, 2009 – Laura Beil
Trying Something New
February 18, 2009 – Nicole LeBrasseur, PhD
The Good Cancer?
February 18, 2009 – Charlotte Huff
Letters from Our Readers
February 18, 2009
The Medicare Prognosis
February 18, 2009 – Teresa McUsic
The Final Journey: The Life and Death of Judy Abernathy
October 05, 2009 – Kathy LaTour
Web Exclusive: What Is a "Good Death?"
April 01, 2009 – Kathy LaTour
Web Exclusive: Resolving Your Own Death
March 25, 2009 – Kathy LaTour
Web Exclusive: Understanding Hospice
March 20, 2009 – The American Hospice Foundation
Web Exclusive: Find a Clinical Trial That's Right for You
March 18, 2009
Web Exclusive: Find a Clinical Trial That's Right for You
March 18, 2009
Web Exclusive: Eulogy for Dr. Phillip Berman
March 18, 2009
Web Exclusive: A Granddaughter's Eulogy
March 17, 2009 – Heather Venrick
Calming Cancer Pain
March 17, 2009 – Kathy LaTour
Excerpt: When Hormone Therapy Can Stress You Out
March 17, 2009 – Ed Weinsberg
Treatment Snapshot
March 17, 2009
Choosing the Right Plan
March 13, 2009 – Christy Schmidt
Currently Viewing
Lymphoma, Myeloma & Prostate Cancer
March 13, 2009 – Elizabeth Whittington
Web Exclusive: Caregiving Resources
March 13, 2009
What Can Patients Do to Reduce a Spouse's Stress?
March 13, 2009 – Lacey Meyer
Web Exclusive: Childhood Survivors Face Increased Risks
March 13, 2009 – Teresa McUsic
Soy Story
March 13, 2009 – Lena Huang
Web Exclusive: An Amazing Journey with Remarkable Women
March 13, 2009 – Kathy LaTour
An Incredible Journey
March 13, 2009 – Kathy LaTour
Web Exclusive: Identifying Insurance Challenges (and Solutions)
March 13, 2009 – Elizabeth Whittington
Medicare Resources
March 13, 2009
New Legislation Focuses on Helping Patients
March 13, 2009 – Teresa McUsic
The Four Parts of Medicare
March 13, 2009
Should Breast Cancer Patients Make the Switch?
March 13, 2009 – Beverly A. Caley
Web Exclusive: Types of Non-Hodgkin Lymphoma
March 13, 2009 – The American Cancer Society
Web Exclusive: Cognitive Changes
March 13, 2009
Web Exclusive: Types of Thyroid Cancer
March 13, 2009 – The National Cancer Institute
My Extended Vacation
March 13, 2009 – Gary Grieger
Does Treatment Differ for Older Patients?
March 13, 2009 – Heather L. Van Epps, PhD
New Blood
March 13, 2009 – Susan Kreimer
For the Caregiver: Brain Nourishment
March 13, 2009 – Laura Beil
The Low-Iodine Diet
March 13, 2009 – Charlotte Huff
Conquer Prostate Cancer: How Medicine, Faith, Love and Sex Can Renew Your Life
March 13, 2009 – Kathy LaTour
Childhood Cancer Survivors Skip Needed Mammograms
March 13, 2009 – Elizabeth Whittington
Young Patients Make Their Mark in Art Exhibit
March 13, 2009 – Lacey Meyer
U.S. Surgeon General's Office Releases Updated Family Health History Program
March 13, 2009 – Lacey Meyer
Kathy Bates Reveals Her Survivorship Status
March 13, 2009 – Lacey Meyer
Q&A: KRAS Testing
March 13, 2009 – Len Lichtenfeld, MD
Supplements Offer No Prostate Cancer Protection
March 13, 2009 – Lena Huang
Crossing Gender Lines
March 13, 2009 – Kathy LaTour
CancerCare Telephone Education Workshop: Seventh Annual Cancer Survivorship Series
March 13, 2009 – Elizabeth Whittington
Ad Campaign Targets Health Care Reform
March 13, 2009 – Elizabeth Whittington
Message From the Editor
March 13, 2009 – Debu Tripathy, MD
Treatment Updates
February 18, 2009 – Susan R. Peck, PhD
The Ins and Outs of Ports
February 18, 2009 – Curtis Pesmen
Stressed Out
February 18, 2009 – Lacey Meyer
Battling Cancer Again
February 18, 2009 – Teresa McUsic
Warrior Survivors
February 18, 2009 – Kathy LaTour
Mind Games
February 18, 2009 – Laura Beil
Trying Something New
February 18, 2009 – Nicole LeBrasseur, PhD
The Good Cancer?
February 18, 2009 – Charlotte Huff
Letters from Our Readers
February 18, 2009
The Medicare Prognosis
February 18, 2009 – Teresa McUsic
The Final Journey: The Life and Death of Judy Abernathy
October 05, 2009 – Kathy LaTour

Lymphoma, Myeloma & Prostate Cancer

FDA approves Mozobil for non-Hodgkin lymphoma and myeloma, and Degarelix for advanced prostate cancer. 

BY Elizabeth Whittington
PUBLISHED March 13, 2009

The Food and Drug Administration approved Mozobil (plerixafor) in December for patients with non-Hodgkin lymphoma and multiple myeloma who are undergoing a stem cell transplant. The injectable drug, given in combination with a growth factor called granulocyte-colony stimulating factor (G-CSF), boosts the number of stem cells in the blood, where they can be collected for transplantation.

In autologous stem cell transplantation, a patient’s stem cells are collected (called apheresis) before high-dose chemotherapy and/or radiation. The high-dose therapy kills cancer cells, but also destroys stem cells that develop into other blood cells. To counter this effect, patients are reinfused with the collected stem cells.

Typically, apheresis requires up to four hours over several days, but Mozobil appears to make the process faster and more successful. A study involving NHL patients found that in up to four apheresis attempts, 59 percent of patients taking G-CSF plus Mozobil had successful stem cell collections compared with 20 percent of patients receiving only G-CSF. Results were similar in a study with multiple myeloma patients. Adding Mozobil allowed patients to reach an adequate number of collected stem cells in a median of one day compared with four days using G-CSF alone. Side effects of Mozobil include fatigue, nausea, and diarrhea.

For more information, visit www.mozobil.com or call 877-466-9624 (site is owned by Genzyme, maker of Mozobil).

Degarelix, a type of hormonal therapy, was approved by the Food and Drug Administration for advanced hormone-dependent prostate cancer at the end of December. At press time, possible trade names were still being reviewed by the FDA.

Degarelix, an injectable gonadotrophin-releasing hormone (GnRH) blocker, reduces levels of testosterone, a hormone produced by the testes and adrenal glands that can drive the growth of some prostate cancers. This has been shown to lower prostate-specific antigen, a measure of the amount of prostate cancer.

The FDA based its approval on phase III studies that compared degarelix with another GnRH blocker called Lupron (leuprolide), a standard treatment for advanced prostate cancer. Degarelix came out on top in the studies, primarily because of the drug’s unique mechanism of action.

Degarelix works by binding to the receptors of the brain’s pituitary cells, blocking the production of luteinizing hormone (a hormone that stimulates the testes to produce testosterone). Patients taking degarelix do not experience the initial “flare” of hormone levels (and possible cancer growth) that is seen with other GnRH blockers such as Lupron.

Phase III studies have confirmed that degarelix suppresses testosterone levels and PSA faster than Lupron without causing the initial hormone flare and cancer growth. In a phase III study published in the British Journal of Urology International, 95 percent of patients taking degarelix achieved complete testosterone suppression on the third day of treatment compared with zero percent of patients taking Lupron. After two weeks, nearly 100 percent of degarelix patients had hormone suppression, while only 18 percent of patients on Lupron reached a comparable level.

Common side effects of degarelix, such as fatigue, weight gain, and hot flashes, were comparable to Lupron, although degarelix was associated with more injection-site skin reactions. For more information, visit www.prostatecancerliving.com (site is owned by Ferring Pharmaceuticals, maker of degarelix). 

Continue the conversation on CURE’s forum. >>
Talk about this article with other patients, caregivers, and advocates in the CURE discussion group.

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In